{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,28]],"date-time":"2025-10-28T03:19:42Z","timestamp":1761621582821,"version":"build-2065373602"},"reference-count":33,"publisher":"MDPI AG","issue":"11","license":[{"start":{"date-parts":[[2021,5,30]],"date-time":"2021-05-30T00:00:00Z","timestamp":1622332800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JCM"],"abstract":"<jats:p>The aim of this paper is to summarise our own and to review published experience regarding the long-term outcome of intravitreal treatment for macular neovascularisation (MNV) secondary to Sorsby\u2019s fundus dystrophy (SFD). A systematic literature search using the MeSH terms [Sorsby] and [anti-vascular endothelial growth factor (VEGF)] was conducted in NCBI\/PubMed, Cochrane Central Register of Controlled Trials (CENTRAL), ScienceDirect, Google Scholar and ClinicalTrials.gov to identify publications reporting anti-VEGF treatment outcomes in SFD. Treatment outcomes were extracted for this meta-analysis from 14 publications and an own patient reporting a total of 31 cases with a mean follow-up (FU) of 54 months. Both eyes were affected in ten (32.3%) instances. Heterogenous reporting limited the comparability of the outcomes. All papers in common, however, reported satisfied to excellent responses to anti-VEGF therapy if patients were diagnosed and treated immediately after onset of symptoms. Of 20 eyes, for which visual acuity was reported before and after treatment, five worsened and seven improved by more than 1 line, whereas eight eyes maintained their function by end of the follow up, and 11 eyes (55%) maintained a driving vision (Snellen VA \u2265 0.5). Of six eyes with a VA &lt; 0.5, VA improved in one to VA \u2265 0.5, whereas of 14 eyes with an initial VA \u2265 0.5, this dropped to &lt;0.5 despite therapy. In MNV secondary to SFD, the delay between first symptoms and access to anti-VEGF treatment determines subretinal scar formation and thereby, functional prognosis. If treated early, this is generally favourable under regular controls and a consequent anti-VEGF treatment of MNV activity.<\/jats:p>","DOI":"10.3390\/jcm10112433","type":"journal-article","created":{"date-parts":[[2021,5,31]],"date-time":"2021-05-31T01:51:37Z","timestamp":1622425897000},"page":"2433","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Visual Outcome after Intravitreal Anti-VEGF Therapy for Macular Neovascularisation Secondary to Sorsby\u2019s Fundus Dystrophy: A Systematic Review"],"prefix":"10.3390","volume":"10","author":[{"given":"Arthur","family":"Baston","sequence":"first","affiliation":[{"name":"Swiss Eye Institute, Rotkreuz, and Retina Clinic, Berner Augenklinik am Lindenhofspital, 3012 Bern, Switzerland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7705-1103","authenticated-orcid":false,"given":"Christin","family":"Gerhardt","sequence":"additional","affiliation":[{"name":"Swiss Eye Institute, Rotkreuz, and Retina Clinic, Berner Augenklinik am Lindenhofspital, 3012 Bern, Switzerland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Souska","family":"Zandi","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, Inselspital, Bern University Hospital, University of Bern, 3010 Bern, Switzerland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3973-5082","authenticated-orcid":false,"given":"Justus G.","family":"Garweg","sequence":"additional","affiliation":[{"name":"Swiss Eye Institute, Rotkreuz, and Retina Clinic, Berner Augenklinik am Lindenhofspital, 3012 Bern, Switzerland"},{"name":"Department of Ophthalmology, Inselspital, Bern University Hospital, University of Bern, 3010 Bern, Switzerland"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2021,5,30]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1136\/bjo.33.2.67","article-title":"A Fundus Dystrophy with Unusual Features (Late onset and dominant inheritance of a central retinal lesion showing oedema, haemorrhage and exudates developing into generalised choroidal atrophy with massive pigment proliferation)","volume":"33","author":"Sorsby","year":"1949","journal-title":"Br. J. Ophthalmol."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1038\/eye.1988.23","article-title":"Sorsby\u2019s pseudoinflammatory macula dystrophy\u2014Sorsby\u2019s fundus dystrophies","volume":"2","author":"Capon","year":"1988","journal-title":"Eye"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1038\/ng0995-27","article-title":"Night blindness in Sorsby\u2019s fundus dystrophy reversed by vitamin A","volume":"11","author":"Jacobson","year":"1995","journal-title":"Nat. Genet."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1002\/ijc.20945","article-title":"Metalloproteinases and their inhibitors in tumor angiogenesis","volume":"115","author":"Handsley","year":"2005","journal-title":"Int. J. Cancer"},{"key":"ref_5","doi-asserted-by":"crossref","unstructured":"Qi, J.H., Ebrahem, Q., Ali, M., Cutler, A., Bell, B., Prayson, N., Sears, J., Knauper, V., Murphy, G., and Anand-Apte, B. (2013). Tissue Inhibitor of Metalloproteinases-3 Peptides Inhibit Angiogenesis and Choroidal Neovascularization in Mice. PLoS ONE, 8.","DOI":"10.1371\/journal.pone.0055667"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1038\/nm846","article-title":"A novel function for tissue inhibitor of metalloproteinases-3 (TIMP3): Inhibition of angiogenesis by blockage of VEGF binding to VEGF receptor-2","volume":"9","author":"Qi","year":"2003","journal-title":"Nat. Med."},{"key":"ref_7","first-page":"323","article-title":"Tissue inhibitor of metalloproteinases-3 is a compo-nent of Bruch\u2019s membrane of the eye","volume":"150","author":"Fariss","year":"1997","journal-title":"Am. J. Pathol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"3579","DOI":"10.1093\/hmg\/ddi385","article-title":"Sorsby\u2019s fundus dystrophy mutations impair turnover of TIMP-3 by retinal pigment epithelial cells","volume":"14","author":"Langton","year":"2005","journal-title":"Hum. Mol. Genet."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/j.exer.2017.08.014","article-title":"Sorsby fundus dystrophy\u2014A review of pathology and disease mechanisms","volume":"165","author":"Christensen","year":"2017","journal-title":"Exp. Eye Res."},{"key":"ref_10","first-page":"88","article-title":"Sorsby fundus dystrophy:Insights from the past and looking to the future","volume":"97","author":"Chao","year":"2018","journal-title":"J. Neurosci. Res."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.ajo.2008.03.024","article-title":"Clinical Course and Treatment Outcomes of Sorsby Fundus Dystrophy","volume":"146","author":"Sivaprasad","year":"2008","journal-title":"Am. J. Ophthalmol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"656","DOI":"10.1016\/j.ophtha.2013.10.019","article-title":"Risk of Scar in the Comparison of Age-related Macular Degeneration Treatments Trials","volume":"121","author":"Daniel","year":"2014","journal-title":"Ophthalmology"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"1755","DOI":"10.1016\/S0161-6420(89)32647-9","article-title":"Sorsby\u2019s Fundus Dystrophy","volume":"96","author":"Hamilton","year":"1989","journal-title":"Ophthalmology"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"1763","DOI":"10.1016\/S0161-6420(89)32654-6","article-title":"Sorsby\u2019s Fundus Dystrophy: A clinical study","volume":"96","author":"Polkinghorne","year":"1989","journal-title":"Ophthalmology"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"1555","DOI":"10.1016\/j.ophtha.2015.04.035","article-title":"Reticular Pseudodrusen in Sorsby Fundus Dystrophy","volume":"122","author":"Gliem","year":"2015","journal-title":"Ophthalmology"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"2017220488","DOI":"10.1136\/bcr-2017-220488","article-title":"Bilateral choroidal neovascular membrane in a young patient with Sorsby fundus dystrophy: The value of prompt treatment","volume":"2017","author":"Menassa","year":"2017","journal-title":"BMJ Case Rep."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"2664","DOI":"10.1167\/iovs.14-15733","article-title":"Sorsby Fundus Dystrophy: Novel Mutations, Novel Phenotypic Characteristics, and Treatment Outcomes","volume":"56","author":"Gliem","year":"2015","journal-title":"Investig. Opthalmol. Vis. Sci."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1097\/00006982-199414040-00006","article-title":"Recurrent Choroidal Neovascularization after Laser Photocoagulation in Sorsby\u02bcs Fundus Dystrophy","volume":"14","author":"Holz","year":"1994","journal-title":"Retina"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1097\/ICB.0000000000000103","article-title":"Altering the Clinical Course of Sorsby Fundus Dystrophy with the Use of Anti-Vascular Endothelial Growth Factor Intraocular Therapy","volume":"9","author":"Keller","year":"2015","journal-title":"Retin. Cases Brief Rep."},{"key":"ref_20","doi-asserted-by":"crossref","unstructured":"Spaide, R.F. (2019). Long-Term Visual Acuity Preservation in Sorsby Fundus Dystrophy with Corticosteroid Treatment. Retin. Cases Brief Rep.","DOI":"10.1097\/ICB.0000000000000946"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1097\/ICB.0b013e318267101e","article-title":"Atypical Sorsby Fundus Dystrophy with a Novel Tyr159cys Timp-3 Mutation","volume":"7","author":"Fung","year":"2013","journal-title":"Retin. Cases Brief Rep."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1089\/jop.2011.0206","article-title":"Intravitreal Anti-Vascular Endothelial Growth Factor Therapy for Choroidal Neovascularization Due to Sorsby Macular Dystrophy","volume":"29","author":"Kapoor","year":"2013","journal-title":"J. Ocul. Pharmacol. Ther."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1097\/00006982-200504000-00024","article-title":"Choroidal Neovascularization in Sorsby Fundus Dystrophy Treated with Photodynamic Therapy and Intravitreal Triamcinolone Acetonide","volume":"25","author":"Peiretti","year":"2005","journal-title":"Retina"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"796","DOI":"10.1136\/bjo.87.6.796","article-title":"Successful photodynamic therapy for subretinal neovascularisation due to Sorsby\u2019s fundus dystrophy: 1 year follow up","volume":"87","author":"Wong","year":"2003","journal-title":"Br. J. Ophthalmol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1177\/001316446002000104","article-title":"A Coefficient of Agreement for Nominal Scales","volume":"20","author":"Cohen","year":"1960","journal-title":"Educ. Psychol. Meas."},{"key":"ref_26","first-page":"3863","article-title":"Treatment with Intravitreal An-ti-VEGF for Choroidal Neovascular Membrane secondary to Sorsby\u2019s Fundus Dystrophy: A 24-Month Analysis","volume":"54","author":"Sanz","year":"2013","journal-title":"Investig. Ophthalmol. Vis. Sci."},{"key":"ref_27","first-page":"229","article-title":"Long-term Outcome of Bevacizumab Therapy in Sorsby Fundus Dystrophy, A Case Series","volume":"58","author":"Kaye","year":"2017","journal-title":"Investig. Ophthalmol. Vis. Sci."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"2016216453","DOI":"10.1136\/bcr-2016-216453","article-title":"OCT angiography in the management of choroidal neovascular membrane secondary to Sorsby fundus dystrophy","volume":"2016","author":"Mohla","year":"2016","journal-title":"BMJ Case Rep."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1177\/1120672118811568","article-title":"Evaluation of Pro-re-Nata (PRN) and Treat and Extend Bevacizumab treatment protocols in Sorsby Fundus Dystrophy","volume":"30","author":"Tsokolas","year":"2018","journal-title":"Eur. J. Ophthalmol."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1097\/ICB.0b013e3181cc216b","article-title":"Successful Treatment of Choroidal Neovascularization Secondary to Sorsby Fundus Dystrophy with Intravitreal Bevacizumab","volume":"5","author":"Gemenetzi","year":"2011","journal-title":"Retin. Cases Brief Rep."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1097\/ICB.0b013e31822476fd","article-title":"Choroidal Neovascularization Secondary to Sorsby Fundus Dystrophy Treated with Intravitreal Bevacizumab","volume":"6","author":"Gray","year":"2012","journal-title":"Retin. Cases Brief Rep."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1038\/eye.2012.221","article-title":"Ranibizumab for the management of Sorsby fundus dystrophy","volume":"27","author":"Balaskas","year":"2012","journal-title":"Eye"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1016\/j.oftal.2011.12.005","article-title":"Tratamiento antiangiog\u00e9nico en fondo de distrofia de Sorsby sin mutaci\u00f3n en gen de TIMP-3","volume":"88","author":"Ruescas","year":"2013","journal-title":"Arch. Soc. Espa\u00f1ola Oftalmol."}],"container-title":["Journal of Clinical Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2077-0383\/10\/11\/2433\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T06:09:07Z","timestamp":1760162947000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2077-0383\/10\/11\/2433"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,5,30]]},"references-count":33,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2021,6]]}},"alternative-id":["jcm10112433"],"URL":"https:\/\/doi.org\/10.3390\/jcm10112433","relation":{},"ISSN":["2077-0383"],"issn-type":[{"type":"electronic","value":"2077-0383"}],"subject":[],"published":{"date-parts":[[2021,5,30]]}}}